Pancreatic Cancer Research

ResearcherPeking University Cancer HospitalNo recent work listed

Jiafu Ji

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-6878-5543; OpenAlex author ID A5079618096. Sources: ClinicalTrials.gov.

Their work

Papers
3
Trials
1 (principal investigator on 1)
Grants
0
Labs led
0
Collaborators
8
Papers, trials and grants by year

2016: 1 paper · 2017: none · 2018: none · 2019: none · 2020: none · 2021: 2 papers, 1 trial

Papers 3

  1. Reduced kinase D‑interacting substrate of 220 kDa (Kidins220) in pancreatic cancer promotes EGFR/ERK signalling and disease progression. Co-author DOI 10.3892/ijo.2021.5214↗
  2. Activated leukocyte cell adhesion molecule (ALCAM)/CD166 in pancreatic cancer, a pivotal link to clinical outcome and vascular embolism. Co-author PMID 35018233↗
  3. IL24 and its Receptors Regulate Growth and Migration of Pancreatic Cancer Cells and Are Potential Biomarkers for IL24 Molecular Therapy. Co-author PMID 26977011↗

Trials 1

  1. Niraparib Combined With Anlotinib in Homologous Recombination Repair (HRR) Gene-mutated Advanced Solid Tumors Principal investigator NCT04764084↗

Closest collaborators

The 8 strongest of 8 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Huiping Li · 1 shared trial, 2021 · strength 0.42
  2. Chunyi Hao · 3 shared papers, 2016–2021 · strength 0.30
  3. Wen G. Jiang · 3 shared papers, 2016–2021 · strength 0.30
  4. Lin Ye · 2 shared papers, 2016–2021 · strength 0.18
  5. Yiming Yang · 1 shared paper, 2021 · strength 0.13
  6. Shuo Cai · 1 shared paper, 2021 · strength 0.11
  7. Bilal A. Al-Sarireh · 1 shared paper, 2021 · strength 0.11
  8. Yongning Jia · 1 shared paper, 2016 · strength 0.07

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.